SCHEDULE: Morgan Stanley Boosts Stake in C4 Therapeutics to 9.3%

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, reported a combined beneficial ownership of 9.3% of C4 Therapeutics, Inc.'s common stock as of December 31, 2025.

Summary

• Morgan Stanley, as a parent holding company, beneficially owns 8,974,191 shares of C4 Therapeutics, Inc. common stock.
• This aggregate amount represents 9.3% of the class of C4 Therapeutics, Inc. common stock.
• Morgan Stanley has shared voting power over 8,973,891 shares and shared dispositive power over 8,974,191 shares.
• Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley, beneficially owns 8,897,942 shares, representing 9.2% of the class.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued institutional confidence in C4 Therapeutics, Inc. by a major financial entity, which can contribute to market stability and investor perception.

Positives

• A major financial institution, Morgan Stanley, maintains a significant beneficial ownership stake of 9.3% in C4 Therapeutics, Inc., indicating continued institutional confidence.
• The holding is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the issuer's future performance or operations, focusing solely on beneficial ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that increased or sustained institutional ownership by a major financial institution like Morgan Stanley often signals confidence in a company's long-term prospects, particularly in the biotechnology sector where C4 Therapeutics operates. Such a significant stake can provide a degree of stability and validation for the company's strategic direction and potential.

Comparison to Industry Standards

• A 9.3% beneficial ownership stake by a single institutional investor like Morgan Stanley is a substantial holding, often exceeding the average institutional stake seen in many small to mid-cap biotechnology companies.
• While specific comparable companies are not mentioned in the filing, such a significant position by a top-tier investment bank is generally viewed favorably, aligning with the trend of large institutions taking meaningful positions in promising biotech firms.

Stakeholder Impact

• Shareholders may view the continued significant institutional ownership by Morgan Stanley as a positive indicator of long-term value and stability for C4 Therapeutics, Inc.

Key Dates

Recommendation

The filing indicates a significant and continued institutional stake by Morgan Stanley, suggesting confidence in C4 Therapeutics. While not a performance report, such a substantial holding by a major financial institution typically provides a level of stability and positive sentiment, warranting a 'hold' for existing investors.

Keywords

C4 Therapeutics, Morgan Stanley, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Beneficial Ownership